Abstract
Treatment with growth factors is an effective method to promote wound healing. Several growth factors have been used in wound treatment, including basic fibroblast growth factor (bFGF) discovered in the 1970s, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and bone morphogenetic protein (BMP). In 2001, Kaken Pharmaceutical Co., Ltd. launched Fiblast Spray in Japan. This product is a topical formulation containing recombinant human bFGF. It is used to treat decubitus ulcers and skin ulcers (burn ulcers and leg ulcers). There is increasing interest in its stimulatory effect on wound healing and its inhibitory effect on scar formation. Wound healing is a physiological phenomenon that involves a complex series of integrated cellular and biochemical responses, characterized by phases of hemostasis, inflammation, proliferation, and maturation. However, much of its detailed mechanism remains unknown. There have been many basic research studies on wound healing using cells and experimental animals. If findings can be used from such studies and clinical practice, development of even more effective treatments might be possible.
Highlights
In 1974, Gospodarowicz reported that a substance in bovine pituitary extract had growth stimulating activity in fibroblasts
Several growth factors have been used in wound treatment, including basic fibroblast growth factor discovered in the 1970s, platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and bone morphogenetic protein (BMP)
Local application of basic fibroblast growth factor (bFGF) can promote dermal and epidermal repair [6,7,8]. These findings have shown that bFGF has unique effects on wound healing that cannot be duplicated by other members of the fibroblast growth factor” (FGF) family
Summary
In 1974, Gospodarowicz reported that a substance in bovine pituitary extract had growth stimulating activity in fibroblasts. He named the substance “fibroblast growth factor” (FGF) [1]. The complete amino acid sequences of the basic FGF (bFGF) and acidic FGF (aFGF) were determined in the 1980s. This information has enabled mass production of recombinant FGF. There are ongoing clinical trials for ulcers, periodontal disease, and bone fractures. A recombinant non-human bFGF is sold in China. It is a recombinant bovine bFGF used to promote wound healing
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have